Literature DB >> 9112358

Involvement of both the classical and alternate pathways of complement in an ex vivo model of xenograft rejection.

M Romanella1, A Aminian, W R Adam, M J Pearse, A J d'Apice.   

Abstract

BACKGROUND: It is now generally accepted that complement activation is critical for the hyperacute rejection of xenografts. Activation of the classical pathway as the result of the interaction of xenoreactive IgM xenoantibodies with the vascular endothelium has been observed in all species combinations examined to date. A number of studies using a variety of species combinations have also implicated alternate pathway involvement; however, these studies do not enable a conclusion to be drawn as to whether the alternate pathway can be activated in the complete absence of classical pathway activation.
METHODS: In this study, human plasma was depleted of both Clq and factor D and then reconstituted with purified Clq or factor D to restore the classical and alternate complement pathways, respectively. The ability of these modified plasmas to prosecute hyperacute rejection was then examined using an ex vivo isolated mouse heart perfusion model based on the Langendorff system. RESULTS AND
CONCLUSIONS: In the mouse to human species combination, both the classical and alternate pathways of complement are independently capable of initiating complement activation and mediating xenograft rejection.

Entities:  

Mesh:

Year:  1997        PMID: 9112358     DOI: 10.1097/00007890-199704150-00020

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

1.  Does expression of a human complement-regulatory protein on xenograft cells protect them from systemic complement activation?

Authors:  Abhijit Jagdale; Huy Nguyen; Juan Li; KaLia Burnette; David Ayares; David K C Cooper; Hidetaka Hara
Journal:  Int J Surg       Date:  2020-09-25       Impact factor: 6.071

2.  An in vivo model of hyperacute rejection: characterization and evaluation of the effect of transgenic human complement inhibitors.

Authors:  M Mora; M Lazzer; G Marsicano; L C Mulder; L Carraresi; A Pieri; A Benanchi; D Grifoni; S Nuti; P Bruzzone; M Comporti; R Cortesini; M Rossini
Journal:  Transgenic Res       Date:  2000-06       Impact factor: 2.788

3.  Bortezomib, C1-inhibitor and plasma exchange do not prolong the survival of multi-transgenic GalT-KO pig kidney xenografts in baboons.

Authors:  S Le Bas-Bernardet; X Tillou; J Branchereau; N Dilek; N Poirier; M Châtelais; B Charreau; D Minault; J Hervouet; K Renaudin; C Crossan; L Scobie; Y Takeuchi; M Diswall; M E Breimer; N Klar; M R Daha; P Simioni; S C Robson; M B Nottle; E J Salvaris; P J Cowan; A J F d'Apice; D H Sachs; K Yamada; I Lagutina; R Duchi; A Perota; G Lazzari; C Galli; E Cozzi; J-P Soulillou; B Vanhove; G Blancho
Journal:  Am J Transplant       Date:  2015-02       Impact factor: 8.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.